Table 1.
Demographics and clinical characteristics of patients at baseline.
| n | % | |
|---|---|---|
| Total number of patients | 142 | 100 |
| Age at the beginning of treatment | ||
| ≤65 years | 83 | 58.5 |
| >65 years | 59 | 41.5 |
| Menopausal status at diagnosis | ||
| Postmenopausal | 116 | 81.7 |
| Premenopausal | 26 | 18.3 |
| Tumour histology | ||
| DCI | 111 | 78.2 |
| LCI | 31 | 21.8 |
| Adjuvant therapy | ||
| Yes | 116 | 81.7 |
| No | 26 | 18.3 |
| Mean DFS | ||
| ≤24 months | 50 | 35.2 |
| >24 months | 92 | 64.8 |
| Site of metastases | ||
| Visceral | 62 | 43.7 |
| Non-visceral | 80 | 56.3 |
| Metastatic pattern | ||
| Oligometastatic | 75 | 52.8 |
| Polymetastatic | 67 | 47.2 |
| Endocrine resistance pattern | ||
| Primary | 21 | 14.8 |
| Secondary | 95 | 66.9 |
| Metastatic at diagnosis | 26 | 18.3 |
| Line of therapy | ||
| First line | 78 | 55 |
| Second line | 33 | 23.2 |
| Beyond second line | 31 | 21.8 |
| Concomitant ET | ||
| Anastrozole | 9 | 6.3 |
| Letrozole | 43 | 30.3 |
| Fulvestrant | 90 | 63.4 |
| Best response | ||
| Complete response | 10 | 7.1 |
| Partial response | 53 | 37.3 |
| Stable disease | 51 | 35.9 |
| Disease progression | 28 | 19.7 |
| Therapy status | ||
| Ongoing | 67 | 47.1 |
| Stopped | 75 | 52.8 |
DFS, disease-free survival.